Cell-Therapy Deals A "Strategic Priority" For Shire
This article was originally published in The Pink Sheet Daily
Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.
You may also be interested in...
Cleveland Clinic spinout Juventas Therapeutics raised $22 million that will help fund mid-stage studies of its adult stem cell treatment.
Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.
Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year
Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding